Immunophotonics
PrivateLast Round
Series C
Sep 1, 2026
Total Funding Raised
$29.8M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Immunophotonics is a biotechnology company that develops novel immunostimulatory drugs designed to enhance routine tumor destruction treatments.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Immunophotonics Comparables
Compare Immunophotonics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Rampart Health | 84% | |
| Syncromune, Inc. | 83% | |
| Highlight Therapeutics | 80% |
Immunophotonics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Sep 1, 2026 | ||||
| Debt | Feb 29, 2024 | ||||
| Grant | Oct 25, 2022 | ||||
| Series B | Apr 6, 2022 | ||||
| Grant | Feb 17, 2022 | ||||
Series A | Sep 3, 2014 |
Key People
Founding team and executive leadership
Immunophotonics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| Zubizoom Investments | Series B |
| iSelect Fund | Series B |
| Arch Grants | Grant |
| Cultivation Capital | Series A |
| Missouri Technology Corporation | Series A |
| St. Louis Arch Angels | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 1, 2026
$10M round raised.
- Apr 18, 2026
Monthly visitors grew 58% MoM, reaching 2.6K.
Recent news
Latest coverage and updates
- hiresSep 1, 2026
Immunophotonics, Inc. hired Robert H. Arch as President and Chief Executive Officer on Sep 1st '26.
- receives_financingSep 1, 2026
Immunophotonics, Inc. received financing of $10M in Series C on Sep 1st '26.
- promotesSep 1, 2026
Immunophotonics, Inc. promoted Robert H. Arch to President and Chief Executive Officer on Sep 1st '26.
Immunophotonics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Immunophotonics's valuation, stock price, and market status.
Is Immunophotonics a public or private company?
Immunophotonics is a private company.
What is the current stock price of Immunophotonics?
Immunophotonics is a private company with no public stock price. No recent secondary market data is available.
How much is Immunophotonics worth (valuation)?
Valuation information for Immunophotonics is not publicly available.
Can I buy Immunophotonics stock?
Immunophotonics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Immunophotonics's last funding round?
Immunophotonics's most recent funding round was Debt on February 29, 2024.
Who are the main investors in Immunophotonics?
Key investors in Immunophotonics include Cultivation Capital, BioGenerator Ventures.
Will Immunophotonics IPO soon?
No public IPO plans have been announced for Immunophotonics.
How can I track Immunophotonics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Immunophotonics's secondary market activity and sign up for updates.